drugset / Trial / NCT02401490
Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy
Phase 4
Unknown
128 enrolled
Hospital Universitari Vall d'Hebron Research Institute
Instituto de Salud Carlos III · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess whether albumin administration after an episode of hepatic encephalopathy (≥ grade II) improves survival at 90 days (mortality endpoint treated as a composite endpoint death and/ or liver transplantation).
Timeline
- Start
- 2015-04
- Primary completion
- 2018-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Albumin | Protein / enzyme biologic | 1 g/kg | — |